Neural stem cell-mediated delivery of oncolytic adenovirus

Julius W. Kim; J. Robert Kane; Jacob S. Young; Alan L. Chang; Deepak Kanojia; Shuo Qian; Drew A. Spencer; Atique U. Ahmed; Maciej S. Lesniak

doi:10.1002/0471142905.hg1311s85

Neural stem cell-mediated delivery of oncolytic adenovirus

Julius W. Kim, J. Robert Kane, Jacob S. Young, Alan L. Chang, Deepak Kanojia, Shuo Qian, Drew A. Spencer, Atique U. Ahmed, Maciej S. Lesniak

Neurological Surgery

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.

Original language	English (US)
Pages (from-to)	13.11.1-13.11.9
Journal	Current protocols in human genetics
Volume	2015
DOIs	https://doi.org/10.1002/0471142905.hg1311s85
State	Published - 2015

Keywords

Cancer
Gene therapy
Mesenchymal stem cell
Neural stem cell
Oncolytic adenovirus

ASJC Scopus subject areas

Genetics
Genetics(clinical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/0471142905.hg1311s85

Cite this

@article{728399c60bc445c5aa4ed5a4c5737b36,

title = "Neural stem cell-mediated delivery of oncolytic adenovirus",

abstract = "The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.",

keywords = "Cancer, Gene therapy, Mesenchymal stem cell, Neural stem cell, Oncolytic adenovirus",

author = "Kim, {Julius W.} and Kane, {J. Robert} and Young, {Jacob S.} and Chang, {Alan L.} and Deepak Kanojia and Shuo Qian and Spencer, {Drew A.} and Ahmed, {Atique U.} and Lesniak, {Maciej S.}",

note = "Publisher Copyright: {\textcopyright} 2015 by John Wiley & Sons, Inc.",

year = "2015",

doi = "10.1002/0471142905.hg1311s85",

language = "English (US)",

volume = "2015",

pages = "13.11.1--13.11.9",

journal = "Current Protocols in Human Genetics",

issn = "1934-8266",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Neural stem cell-mediated delivery of oncolytic adenovirus

AU - Kim, Julius W.

AU - Kane, J. Robert

AU - Young, Jacob S.

AU - Chang, Alan L.

AU - Kanojia, Deepak

AU - Qian, Shuo

AU - Spencer, Drew A.

AU - Ahmed, Atique U.

AU - Lesniak, Maciej S.

PY - 2015

Y1 - 2015

N2 - The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.

AB - The use of stem cells (SCs) as carriers for therapeutic agents has now progressed to early clinical trials. These clinical trials exploring SC-mediated delivery of oncolytic adenoviruses will commence in the near future, hopefully yielding meritorious results that can provoke further scientific inquiry. Preclinical animal studies have demonstrated that SCs can be successfully loaded with conditionally-replicative adenoviruses and delivered to the tumor, whereupon they may evoke pronounced therapeutic efficacy. In this protocol, we describe the maintenance of SCs, provide an analysis of optimal adenoviral titers for SC loading, and evaluate the optimized viral loading on SCs.

KW - Cancer

KW - Gene therapy

KW - Mesenchymal stem cell

KW - Neural stem cell

KW - Oncolytic adenovirus

UR - http://www.scopus.com/inward/record.url?scp=84949256484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949256484&partnerID=8YFLogxK

U2 - 10.1002/0471142905.hg1311s85

DO - 10.1002/0471142905.hg1311s85

M3 - Article

C2 - 25827347

AN - SCOPUS:84949256484

SN - 1934-8266

VL - 2015

SP - 13.11.1-13.11.9

JO - Current Protocols in Human Genetics

JF - Current Protocols in Human Genetics

ER -

Neural stem cell-mediated delivery of oncolytic adenovirus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this